Galectin Therapeutics (GALT) Announces Results from GR-MD-02 Phase 2a; Won't Continue Testing in Psoriasis
Tweet Send to a Friend
Galectin Therapeutics (Nasdaq: GALT) announces interim results from an exploratory, open-label, Phase 2a clinical trial with GR-MD-02 in patients with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
